Neuroinflammation is a major contributor to the progressive brain injury process induced by traumatic brain injury (TBI), and may play an important role in the pathophysiology of axonal injury. The immediate neuroinflammatory cascade cannot be characterized in the human setting. Therefore, we used the midline fluid percussion injury model of diffuse TBI in rats and a novel microdialysis (MD) method providing stable diffusion-driven biomarker sampling. Immediately post-injury, bilateral amphiphilic tri-block polymer coated MD probes (100 kDa cut off membrane) were inserted and perfused with Dextran 500 kDa-supplemented artificial cerebrospinal fluid (CSF) to optimize protein capture. Six hourly samples were analyzed for 27 inflammatory biomarkers (9 chemokines, 13 cytokines, and 5 growth factors) using a commercial multiplex biomarker kit. TBI (n = 6) resulted in a significant increase compared with sham-injured controls (n = 6) for five chemokines (eotaxin/CCL11, fractalkine/CX3CL1, LIX/CXCL5, monocyte chemoattractant protein [MCP]1α/CCL2, macrophage inflammatory protein [MIP]1α /CCL3), 10 cytokines (interleukin [IL]-1α, IL-1β, IL-4, IL-6, IL-10, IL-13, IL-17α, IL-18, interferon [IFN]-γ, tumor necrosis factor [TNF]-α), and four growth factors (epidermal growth factor [EGF], granulocyte-macrophage colony-stimulating factor [GM-CSF], leptin, vascular endothelial growth factor [VEGF]). Therefore, diffuse TBI was associated with an increased level of 18 of the 27 inflammatory biomarkers at one through six time points, during the observation period whereas the remaining 9 biomarkers were unaltered. The study shows that diffuse TBI induces an acute increase in a number of inflammatory biomarkers. The novel MD technique provides stable MD sampling suitable for further studies on the early neuroinflammatory cascade in TBI.
Get full access to this article
View all access options for this article.
References
1.
MaasA.I., StocchettiN., and BullockR. (2008). Moderate and severe traumatic brain injury in adults. Lancet Neurol. 7, 728–741.
2.
KoliasA.G., GuilfoyleM.R., HelmyA., AllansonJ., and HutchinsonP.J. (2013). Traumatic brain injury in adults. Pract. Neurol., 13, 228–235.
3.
StocchettiN., PaternoR., CiterioG., BerettaL., and ColomboA. (2012). Traumatic brain injury in an aging population. J. Neurotrauma, 29, 1119–1125.
4.
PeetersW., van den BrandeR., PolinderS., BrazinovaA., SteyerbergE.W., LingsmaH.F., and MaasA.I. (2015). Epidemiology of traumatic brain injury in Europe. Acta Neurochir. (Wien) 157, 1683–1696.
5.
MaselB.E., and DeWittD.S. (2010). Traumatic brain injury: a disease process, not an event. J. Neurotrauma, 27, 1529–1540.
6.
PovlishockJ.T., and KatzD.I. (2005). Update of neuropathology and neurological recovery after traumatic brain injury. J. Head Trauma Rehabil., 20, 76–94.
JohnsonV.E., StewartW., and SmithD.H. (2013). Axonal pathology in traumatic brain injury. Exp. Neurol., 246, 35–43.
9.
GreerJ.E., McGinnM.J., and PovlishockJ.T. (2011). Diffuse traumatic axonal injury in the mouse induces atrophy, c-Jun activation, and axonal outgrowth in the axotomized neuronal population. J. Neurosci., 31, 5089–5105.
10.
Ekmark-LewenS., FlygtJ., FridgeirsdottirG.A., KiwanukaO., HanellA., MeyersonB.J., MirA.K., GramH., LewenA., ClausenF., HilleredL., and MarklundN. (2016). Diffuse traumatic axonal injury in mice induces complex behavioural alterations that are normalized by neutralization of interleukin-1beta. Eur. J. Neurosci., 43, 1016–1033.
11.
Ekmark-LewenS., FlygtJ., KiwanukaO., MeyersonB.J., LewenA., HilleredL., and MarklundN. (2013). Traumatic axonal injury in the mouse is accompanied by a dynamic inflammatory response, astroglial reactivity and complex behavioral changes. J. Neuroinflammation, 10, 44.
12.
HelmyA., AntoniadesC.A., GuilfoyleM.R., CarpenterK.L., and HutchinsonP.J. (2012). Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS One, 7, e39677.
13.
HelmyA., CarpenterK.L., SkepperJ.N., KirkpatrickP.J., PickardJ.D., and HutchinsonP.J. (2009). Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. J. Neurotrauma, 26, 549–561.
14.
HelmyA., GuilfoyleM.R., CarpenterK.L., PickardJ.D., MenonD.K., and HutchinsonP.J. (2014). Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J. Cereb. Blood Flow Metab., 34, 845–851.
15.
HelmyA., GuilfoyleM.R., CarpenterK.L., PickardJ.D., MenonD.K., and HutchinsonP.J. (2016). Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury. J. Cereb. Blood Flow Metab., 36, 1434–1448.
16.
HelmyA., CarpenterK.L., MenonD.K., PickardJ.D., and HutchinsonP.J. (2011). The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J. Cereb. Blood Flow Metab., 31, 658–670.
17.
ZeilerF.A., ThelinE.P., CzosnykaM., HutchinsonP.J., MenonD.K., and HelmyA. (2017). Cerebrospinal fluid and microdialysis cytokines in severe traumatic brain injury: a scoping systematic review. Front. Neurol., 8, 331.
18.
PerssonL., and HilleredL. (1992). Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis. J. Neurosurg., 76, 72–80.
HilleredL., VespaP.M., and HovdaD.A. (2005). Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J. Neurotrauma, 22, 3–41.
21.
HillmanJ., AnemanO., AndersonC., SjogrenF., SabergC., and MellergardP. (2005). A microdialysis technique for routine measurement of macromolecules in the injured human brain. Neurosurgery, 56, 1264–1270.
22.
HutchinsonP.J., O'ConnellM.T., NortjeJ., SmithP., Al-RawiP.G., GuptaA.K., MenonD.K., and PickardJ.D. (2005). Cerebral microdialysis methodology—evaluation of 20 kDa and 100 kDa catheters. Physiol. Meas., 26, 423–428.
23.
HelmyA., De SimoniM.G., GuilfoyleM.R., CarpenterK.L., and HutchinsonP.J. (2011). Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog. Neurobiol., 95, 352–372.
24.
MellergardP., AnemanO., SjogrenF., PetterssonP., and HillmanJ. (2008). Changes in extracellular concentrations of some cytokines, chemokines, and neurotrophic factors after insertion of intracerebral microdialysis catheters in neurosurgical patients. Neurosurgery, 62, 151–158.
25.
MarklundN., BlennowK., ZetterbergH., Ronne-EngstromE., EnbladP., and HilleredL. (2009). Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J. Neurosurg.
26.
DahlinA.P., WetterhallM., CaldwellK.D., LarssonA., BergquistJ., HilleredL., and HjortK. (2010). Methodological aspects on microdialysis protein sampling and quantification in biological fluids: an in vitro study on human ventricular CSF. Anal. Chem., 82, 4376–4385.
27.
DahlinA.P., HjortK., HilleredL., SjodinM.O., BergquistJ., and WetterhallM. (2012). Multiplexed quantification of proteins adsorbed to surface-modified and non-modified microdialysis membranes. Anal. Bioanal. Chem., 402, 2057–2067.
28.
ChuJ., KoudriavtsevV., HjortK., and DahlinA.P. (2014). Fluorescence imaging of macromolecule transport in high molecular weight cut-off microdialysis. Anal. Bioanal. Chem., 406, 7601–7609.
29.
KeelerG.D., DurdikJ.M., and StenkenJ.A. (2014). Comparison of microdialysis sampling perfusion fluid components on the foreign body reaction in rat subcutaneous tissue. Eur. J. Pharm. Sci., 57, 60–67.
30.
PurinsK., SedighA., MolnarC., JanssonL., KorsgrenO., LorantT., TufvesonG., WennbergL., WiklundL., LewenA., and EnbladP. (2011). Standardized experimental brain death model for studies of intracranial dynamics, organ preservation, and organ transplantation in the pig. Crit. Care Med., 39, 512–517.
31.
DahlinA.P., PurinsK., ClausenF., ChuJ., SedighA., LorantT., EnbladP., LewenA., and HilleredL. (2014). Refined microdialysis method for protein biomarker sampling in acute brain injury in the neurointensive care setting. Anal. Chem., 86, 8671–8679.
32.
MarklundN., and HilleredL. (2011). Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?. Br. J. Pharmacol., 164, 1207–1229.
33.
FassbenderK., SchneiderS., BertschT., SchlueterD., FatarM., RagoschkeA., KuhlS., KischkaU., and HennericiM. (2000). Temporal profile of release of interleukin-1beta in neurotrauma. Neurosci. Lett., 284, 135–138.
34.
KinnunenK.M., GreenwoodR., PowellJ.H., LeechR., HawkinsP.C., BonnelleV., PatelM.C., CounsellS.J., and SharpD.J. (2011). White matter damage and cognitive impairment after traumatic brain injury. Brain, 134, 449–463.
35.
SmithD.H., and MeaneyD.F. (2000). Axonal damage in traumatic brain injury. Neuroscientist, 6, 483–495.
36.
ArmstrongR.C., MierzwaA.J., MarionC.M., and SullivanG.M. (2016). White matter involvement after TBI: clues to axon and myelin repair capacity. Exp. Neurol., 275, Pt. 3, 328–333.
37.
FlygtJ., DjupsjoA., LenneF., and MarklundN. (2013). Myelin loss and oligodendrocyte pathology in white matter tracts following traumatic brain injury in the rat. Eur. J. Neurosci., 38, 2153–2165.
38.
KelleyB.J., LifshitzJ., and PovlishockJ.T. (2007). Neuroinflammatory responses after experimental diffuse traumatic brain injury. J. Neuropathol. Exp. Neurol., 66, 989–1001.
39.
Morganti-KossmannM.C., SatgunaseelanL., ByeN., and KossmannT. (2007). Modulation of immune response by head injury. Injury, 38, 1392–1400.
40.
MayerC.L., HuberB.R., and PeskindE. (2013). Traumatic brain injury, neuroinflammation, and post-traumatic headaches. Headache, 53, 1523–1530.
41.
ChenW., ShengJ., GuoJ., PengG., HongJ., LiB., ChenX., LiK., and WangS. (2017). Cytokine cascades induced by mechanical trauma injury alter voltage-gated sodium channel activity in intact cortical neurons. J. Neuroinflammation, 14, 73.
42.
ThelinE.P., HallC.E., GuptaK., CarpenterK.L.H., ChandranS., HutchinsonP.J., PataniR., and HelmyA. (2018). Elucidating pro-inflammatory cytokine responses after traumatic brain injury in a human stem cell model. J. Neurotrauma, 35, 341–352.
43.
HillmanJ., AnemanO., PerssonM., AnderssonC., DabrosinC., and MellergardP. (2007). Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis. J. Neurosurg., 106, 820–825.
44.
SuY., FanW., MaZ., WenX., WangW., WuQ., and HuangH. (2014). Taurine improves functional and histological outcomes and reduces inflammation in traumatic brain injury. Neuroscience, 266, 56–65.
45.
RhodesJ.K., SharkeyJ., and AndrewsP.J. (2008). The temporal expression, cellular localization, and inhibition of the chemokines MIP-2 and MCP-1 after traumatic brain injury in the rat. J. Neurotrauma, 26, 507–525.
46.
DalgardC.L., ColeJ.T., KeanW.S., LuckyJ.J., SukumarG., McMullenD.C., PollardH.B., and WatsonW.D. (2012). The cytokine temporal profile in rat cortex after controlled cortical impact. Front. Mol. Neurosci., 5, 6.
47.
McKeeC.A., and LukensJ.R. (2016). Emerging roles for the immune system in traumatic brain injury. Front. Immunol., 7, 556.
GyonevaS., and RansohoffR.M. (2015). Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. Trends Pharmacol. Sci., 36, 471–480.
50.
KarveI.P., TaylorJ.M., and CrackP.J. (2016). The contribution of astrocytes and microglia to traumatic brain injury. Br. J. Pharmacol., 173, 692–702.
51.
Szmydynger-ChodobskaJ., ShanR., ThomasianN., and ChodobskiA. (2016). The involvement of pial microvessels in leukocyte invasion after mild traumatic brain injury. PLoS One, 11, e0167677.
52.
KimC.C., NakamuraM.C., and HsiehC.L. (2016). Brain trauma elicits non-canonical macrophage activation states. J. Neuroinflammation, 13, 117.
53.
JensenC.J., MassieA. and De KeyserJ. (2013). Immune players in the CNS: the astrocyte. J. Neuroimmune Pharmacol., 8, 824–839.
54.
IsraelssonC., BengtssonH., KylbergA., KullanderK., LewenA., HilleredL., and EbendalT. (2008). Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury. J. Neurotrauma, 25, 959–974.
55.
IsraelssonC., BengtssonH., LobellA., NilssonL.N., KylbergA., IsakssonM., WootzH., LannfeltL., KullanderK., HilleredL., and EbendalT. (2010). Appearance of Cxcl10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders. Eur. J. Neurosci., 31, 852–863.
56.
HutchinsonP.J., O'ConnellM.T., RothwellN.J., HopkinsS.J., NortjeJ., CarpenterK.L., TimofeevI., Al-RawiP.G., MenonD.K., and PickardJ.D. (2007). Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J. Neurotrauma, 24, 1545–1557.
57.
SchroderK., HertzogP.J., RavasiT., and HumeD.A. (2004). Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol, 75, 163–189.
58.
WadaK., ChatzipanteliK., KraydiehS., BustoR., and DietrichW.D. (1998). Inducible nitric oxide synthase expression after traumatic brain injury and neuroprotection with aminoguanidine treatment in rats. Neurosurgery, 43, 1427–1436.
59.
ZhangZ., ArteltM., BurnetM., TrautmannK., and SchluesenerH.J. (2006). Early infiltration of CD8+ macrophages/microglia to lesions of rat traumatic brain injury. Neuroscience, 141, 637–644.
60.
GadaniS.P., CronkJ.C., NorrisG.T., and KipnisJ. (2012). IL-4 in the brain: a cytokine to remember. J. Immunol., 189, 4213–4219.
61.
ChaoC.C., MolitorT.W., and HuS. (1993). Neuroprotective role of IL-4 against activated microglia. J. Immunol., 151, 1473–1481.
62.
GraeberM.B. (2010). Changing face of microglia. Science, 330, 783–788.
63.
WoodcockT., and Morganti-KossmannM.C. (2013). The role of markers of inflammation in traumatic brain injury. Front. Neurol., 4, 18.
64.
GuglielmettiC., Le BlonD., SantermansE., Salas-PerdomoA., DaansJ., De VochtN., ShahD., HoornaertC., PraetJ., PeerlingsJ., KaraF., BigotC., MaiZ., GoossensH., HensN., HendrixS., VerhoyeM., PlanasA.M., BernemanZ., van der LindenA., and PonsaertsP. (2016). Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages. Glia, 64, 2181–2200.
65.
WaismanA., HauptmannJ. and RegenT. (2015). The role of IL-17 in CNS diseases. Acta Neuropathol, 129, 625–637.
66.
SongL., PeiL., YaoS., WuY., and ShangY. (2017). NLRP3 Inflammasome in neurological diseases, from functions to therapies. Front. Cell. Neurosci., 11, 63.
67.
Abdul-MuneerP.M., LongM., ConteA.A., SanthakumarV., and PfisterB.J. (2016). High Ca2+ influx during traumatic brain injury leads to caspase-1-dependent neuroinflammation and cell death. Mol Neurobiol.
68.
TruettnerJ.S., SuzukiT., and DietrichW.D. (2005). The effect of therapeutic hypothermia on the expression of inflammatory response genes following moderate traumatic brain injury in the rat. Brain Res. Mol. Brain Res., 138, 124–134.
69.
ShultzS.R., TanX.L., WrightD.K., LiuS.J., SempleB.D., JohnstonL., JonesN.C., CookA.D., HamiltonJ.A., and O'BrienT.J. (2014). Granulocyte-macrophage colony-stimulating factor is neuroprotective in experimental traumatic brain injury. J. Neurotrauma, 31, 976–983.
70.
SunD., BullockM.R., AltememiN., ZhouZ., HagoodS., RolfeA., McGinnM.J., HammR., and ColelloR.J. (2010). The effect of epidermal growth factor in the injured brain after trauma in rats. J. Neurotrauma, 27, 923–938.
71.
ClausenF., LindhT., SalimiS., and ErlandssonA. (2014). Combination of growth factor treatment and scaffold deposition following traumatic brain injury has only a temporary effect on regeneration. Brain Res. 1588, 37–46.
72.
TadoM., MoriT., FukushimaM., OshimaH., MaedaT., YoshinoA., AizawaS., and KatayamaY. (2014). Increased expression of vascular endothelial growth factor attenuates contusion necrosis without influencing contusion edema after traumatic brain injury in rats. J. Neurotrauma, 31, 691–698.
73.
LeeC., and AgostonD.V. (2010). Vascular endothelial growth factor is involved in mediating increased de novo hippocampal neurogenesis in response to traumatic brain injury. J. Neurotrauma, 27, 541–553.
74.
YangD.Y., ChenY.J., WangM.F., PanH.C., ChenS.Y., and ChengF.C. (2010). Granulocyte colony-stimulating factor enhances cellular proliferation and motor function recovery on rats subjected to traumatic brain injury. Neurol. Res., 32, 1041–1049.
75.
KozaiT.D.Y., Jaquins-GerstlA.S., VazquezA.L., MichaelA.C., and CuiX.T. (2016). Dexamethasone retrodialysis attenuates microglial response to implanted probes in vivo. Biomaterials, 87, 157–169.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
